Lenzing Aktie 428654 / AT0000644505
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
19.09.2025 08:05:53
|
EQS-News: Lenzing AG extends Christian Skilich's Management Board mandate until 2029 – Mathias Breuer promoted to CFO with January 1, 2026
|
EQS-News: Lenzing AG
/ Key word(s): Personnel
Lenzing AG extends Christian Skilich's Management Board mandate until 2029 – Mathias Breuer promoted to CFO with January 1, 2026
Lenzing, September 19, 2025 – The Supervisory Board of Lenzing AG has extended the standing management board mandate of Chief Pulp & Chief Technology Officer Christian Skilich, running until May 2026, by three additional years until May 31, 2029.
Christian Skilich has been a member of the Management Board of Lenzing AG since June 2020. As Chief Pulp & Chief Technology Officer, his responsibilities, among others, include Pulp Commercial and Operations, Co-Products & Wood as well as Global HSE, Purchasing, and Innovation.
Patrick Lackenbucher, Chairman of the Supervisory Board of Lenzing AG, says: “We are delighted that Christian Skilich will continue to serve as member of Lenzing AG’s Management Board going forward. The pulp business under his leadership is an important and successful profit driver and underpins the company's integrated business model. The innovation portfolio, which falls within his area of responsibility as well, will play a key role in shaping the future of Lenzing AG.”
CFO Nico Reiner will not renew his contract at the end of 2025. Mathias Breuer to become new CFO in 2026 CFO Nico Reiner has informed the Supervisory Board of Lenzing AG that he will not be available to extend his Management Board mandate, which expires on December 31, 2025. The Supervisory Board respects his decision and thanks Nico Reiner for his outstanding achievements on the Management Board of Lenzing AG, which, in addition to significant improvements in earnings, also included the successful completion of major refinancing projects in recent years.
Supervisory Board Chairman Lackenbucher says: “We would like to thank Nico Reiner for his commitment and outstanding achievements as Chief Financial Officer of Lenzing AG. Nico Reiner has made a significant contribution to improving earnings and optimizing the financing structure of Lenzing AG. His prudence and expertise have contributed significantly to the stability and future of the company in a challenging macroeconomic environment.”
Mathias Breuer (42) will become new Chief Financial Officer on January 1, 2026. Breuer has been part of the management team at Lenzing AG since 2023 and has been instrumental for the development and successful implementation of the company-wide performance program. Prior to that, he served as CFO of the packaging group Adapa and as CFO of the Sempermed division of Semperit AG Holding.
Lackenbucher: “With Mathias Breuer, an experienced Lenzing manager and financial expert will join the company's Management Board as CFO in 2026. The fact that we can fill this position internally speaks for the quality of the management team at Lenzing AG. With the appointment of Mathias Breuer, we are ensuring a continued focus on the implementation and further development of the ongoing performance measures, to further strengthen the profitability and competitiveness of Lenzing AG in the global market.”
“I would like to thank Nico Reiner for his commitment during a crucial phase at Lenzing AG. He has further developed our financial organization and thus contributed significantly to the company's success,” adds CEO Rohit Aggarwal. “At the same time, I welcome the decision of the Supervisory Board – with Mathias Breuer, we are gaining an outstanding financial expert who is deeply familiar with our company and industry. He has played a central role in the company’s transformation process so far and is ideally suited to shape the next phase of our financial strategy.” Photo-Download: https://mediadb.lenzing.com/pinaccess/showpin.do?pinCode=lO4jLxDGHKGN
19.09.2025 CET/CEST This Corporate News was distributed by EQS Group. www.eqs.com |
| Language: | English |
| Company: | Lenzing AG |
| 4860 Lenzing | |
| Austria | |
| Phone: | +43 7672-701-0 |
| Fax: | +43 7672-96301 |
| E-mail: | office@lenzing.com |
| Internet: | www.lenzing.com |
| ISIN: | AT0000644505 |
| Indices: | ATX |
| Listed: | Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2200058 |
| End of News | EQS News Service |
|
|
2200058 19.09.2025 CET/CEST
Nachrichten zu Lenzing AG
|
07.11.25 |
Zurückhaltung in Wien: ATX Prime präsentiert sich zum Ende des Freitagshandels leichter (finanzen.ch) | |
|
07.11.25 |
Angespannte Stimmung in Wien: ATX präsentiert sich schlussendlich leichter (finanzen.ch) | |
|
07.11.25 |
ATX Prime aktuell: ATX Prime am Freitagnachmittag mit Abgaben (finanzen.ch) | |
|
07.11.25 |
Verluste in Wien: So performt der ATX am Freitagnachmittag (finanzen.ch) | |
|
07.11.25 |
Starker Wochentag in Wien: ATX Prime am Mittag in Grün (finanzen.ch) | |
|
07.11.25 |
Gewinne in Wien: ATX mittags mit Kursplus (finanzen.ch) | |
|
06.11.25 |
Schwache Performance in Wien: ATX Prime beendet die Donnerstagssitzung mit Verlusten (finanzen.ch) | |
|
06.11.25 |
Schwacher Handel: ATX beendet den Donnerstagshandel im Minus (finanzen.ch) |
Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer
Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉
Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.
💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht wenig bewegt ins Wochenende -- DAX schliesslich mit Abgaben -- Wall Street beenden Handel uneins -- Asiens Börsen letztlich schwächerDer heimische Aktienmarkt tendierte am Freitag seitwärts, während der deutsche Aktienmarkt sich abwärts bewegte. An der Wall Street ging es am Freitag in unterschiedliche Richtungen. An den Märkten in Fernost ging es zum Wochenende nach unten.


